Medicare Enrolled
Dr. Thomas Lowe, M.D.
Hematology & Oncology · Torrance, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lowe from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lowe?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lowe
Dr. Thomas Lowe is a hematology & oncology specialist in Torrance, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Lowe performed 88,711 Medicare services across 1,695 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lowe received a total of $1,442 from 17 pharmaceutical and/or device companies across 64 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lowe is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 9% volume in CA
$1,442 industry payments
Medicare Practice Summary
Medicare Utilization ↗88,711
Medicare services
Top 9% in CA for hematology & oncology
1,695
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,669 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
32,207 | $0 | $3 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
27,600 | $0 | $3 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 17,452 | $0 | $3 |
| Injection, granisetron hydrochloride, 100 mcg | 2,730 | $0 | $5 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,488 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,676 | $8 | $15 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
670 | $26 | $54 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
549 | $68 | $135 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
434 | $118 | $300 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
428 | $66 | $135 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
379 | $149 | $250 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
337 | $104 | $180 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
289 | $6 | $270 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
237 | $12 | $38 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
225 | $14 | $38 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
207 | $69 | $70 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
149 | $58 | $135 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
128 | $25 | $70 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
114 | $56 | $119 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
109 | $99 | $210 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
60 | $138 | $270 |
| New patient office visit, complex (60-74 min) | 49 | $175 | $340 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
43 | $5 | $10 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
41 | $50 | $125 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
35 | $12 | $25 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
30 | $1 | $6 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
17 | $83 | $165 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
16 | $136 | $390 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
12 | $70 | $172 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.5% high complexity
94.5% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,442
Total received (2018-2024)
Avg $288/year across 5 years
Bottom 39% in CA for hematology & oncology
17
Companies
64
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,400 (97.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$42 (2.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$744
2023
$552
2022
$88
2021
$46
2018
$13
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$185
Eisai Inc.
$169
Dendreon Pharmaceuticals LLC
$165
ARRAY BIOPHARMA INC
$53
PFIZER INC.
$52
Genentech USA, Inc.
$46
ABBVIE INC.
$28
Merck Sharp & Dohme LLC
$25
GlaxoSmithKline, LLC.
$20
Top 3 companies account for 69.8% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$356
Eisai Inc.
$213
Dendreon Pharmaceuticals LLC
$165
Genentech USA, Inc.
$151
PFIZER INC.
$146
GlaxoSmithKline, LLC.
$61
ARRAY BIOPHARMA INC
$53
ABBVIE INC.
$48
Amgen Inc.
$43
Mirati Therapeutics, Inc.
$42
Merck Sharp & Dohme LLC
$41
Celgene Corporation
$32
Bayer HealthCare Pharmaceuticals Inc.
$22
Kyowa Kirin, Inc.
$22
Mylan Institutional Inc.
$20
Janssen Biotech, Inc.
$13
Tactile Systems Technology Inc
$12
Top 3 companies account for 50.9% of all-time payments
Associated products mentioned in payments ›
BRAFTOVI · CALQUENCE · Columvi · EPKINLY · Erleada · Flexitouch Plus · IBRANCE · JEMPERLI · KEYTRUDA · KRAZATI · LUMAKRAS · Lenvima · Lunsumio · Nplate · Ogivri · POTELIGEO · PROVENGE · REBLOZYL · Stivarga · Tecentriq · VENCLEXTA · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
322
Per 100K population
3.3
County median income
$87,760
Nearest hospital
DEL AMO HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lowe is a mixed practice specialist, with above-average Medicare volume (top 9% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lowe experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Lowe performed 32,207 oxaliplatin chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lowe receive payments from pharmaceutical companies?
Yes. Dr. Lowe received a total of $1,442 from 17 companies across 64 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lowe's costs compare to other hematology & oncology specialists in Torrance?
Dr. Lowe's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lowe) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Torrance
Browse hematology & oncology specialists in Torrance ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
By company
Dendreon Pharmaceuticals LLC Payments to Doctors
See all physicians who received payments from Dendreon Pharmaceuticals LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology